Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

Ticagrelor in ACS—what does PLATO teach us?

Nature Reviews Cardiology volume 6, pages 737–738 (2009)Cite this article

The novel antiplatelet agent ticagrelor was evaluated against clopidogrel in the PLATO trial of patients with acute coronary syndromes. This article discusses the main findings and importance of this study, including the reduction in mortality associated with ticagrelor therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanism of action of ticagrelor.

References

  1. Wallentin, L. et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).

    Google Scholar 

  2. Bhatt, D. L. & Topol, E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. 2, 15–28 (2003).

    Article  CAS  PubMed  Google Scholar 

  3. Yusuf, S. et al. for the CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494–502 (2001).

    Google Scholar 

  4. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).

    Article  CAS  PubMed  Google Scholar 

  5. Bhatt, D. L. Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI? Nat. Clin. Pract. Cardiovasc. Med. 5, 252–253 (2008).

    Article  PubMed  Google Scholar 

  6. Bhatt, D. L. Prasugrel in clinical practice. N. Engl. J. Med. 361, 940–942 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329–1339 (1996).

  8. Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411–2420 (2002).

    Article  CAS  PubMed  Google Scholar 

  9. Bavry, A. A. & Bhatt, D. L. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 371, 2134–2143 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Bhatt, D. L. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 302, 896–897 (2009).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Veterans Affairs Boston Healthcare System and Brigham and Women's Hospital, Boston, MA, USA

    Deepak L. Bhatt

Authors
  1. Deepak L. Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak L. Bhatt.

Ethics declarations

Competing interests

D. L. Bhatt has received research grants to his institution for studies in which he served as primary investigator from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape Technologies, Sanofi-Aventis, and The Medicines Company. He has served as a consultant, or as a member of the Advisory Board (honoraria waived or donated for >3 years), for Arena Pharmaceuticals, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Cardax, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, Ortho-McNeil, Otsuka, Paringenix, PDL BioPharma, Philips, Portola Pharmaceuticals, Sanofi-Aventis, Schering-Plough, Takeda, The Medicines Company, and Vertex.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhatt, D. Ticagrelor in ACS—what does PLATO teach us?. Nat Rev Cardiol 6, 737–738 (2009). https://doi.org/10.1038/nrcardio.2009.192

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.192

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing